AbbVie's elezanumab on Sept. 29 received Fast Track designation for the treatment of patients with spinal cord injury.
Elezanumab, a monoclonal antibody, was designed by the biopharmaceutical company to block a molecule that can hinder neuronal regeneration and functional recovery after central nervous system damage.
AbbVie is developing elezanumab for spinal cord injuries, multiple sclerosis and acute ischemic stroke.
The FDA has also granted elezanumab orphan status, which decreases development costs and could increase profits if approved.